REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

  • STATUS
    Recruiting
  • End date
    Aug 8, 2024
  • participants needed
    57
  • sponsor
    Regeneron Pharmaceuticals
Updated on 12 July 2022

Summary

The primary objective of this study is to assess the safety and tolerability of REGN7257 in patients with immunosuppressive therapy (IST)-refractory or IST-relapsed severe aplastic anemia (SAA). An additional primary objective (for Part B only) is to evaluate the clinical efficacy of REGN7257 in patients with IST-refractory or IST-relapsed SAA.

The secondary objectives of this study are to assess the following for REGN7257:

  • Clinical response over time
  • Maintenance of response
  • Impact on transfusion requirements
  • Effect on blood counts and cell populations
  • Pharmacokinetics (PK)
  • Immunogenicity

Details
Condition Severe Aplastic Anemia (SAA)
Treatment REGN7257
Clinical Study IdentifierNCT04409080
SponsorRegeneron Pharmaceuticals
Last Modified on12 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

SAA that is IST-refractory or IST-relapsed, as defined in the protocol
Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a treatment option or has been refused by the patient
Adequate hepatic and renal function as defined in the protocol

Exclusion Criteria

Diagnosis of Fanconi anemia or other congenital bone marrow failure syndrome as defined in the protocol
Evidence of myelodysplastic syndrome as defined in the protocol
Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of clinically significant hemolysis (eg, treatment indicated) or history of PNH-associated thrombosis
Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior to dosing
Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing as defined in the protocol
Treatment with eltrombopag or investigational thrombopoietin receptor agonist, Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2 weeks prior to dosing
HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit as defined in the protocol
Active tuberculosis, latent tuberculosis infection (LTBI) or history incompletely-treated tuberculosis or LTBI
Note: Other protocol-defined inclusion/ exclusion criteria apply
Active infection as defined in the protocol including COVID-19
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note